Corcept Therapeutics Inc (NASDAQ:CORT)
| Market Cap | 12.60B+32.2% |
| Revenue (ttm) | 830.81M+16.0% |
| Net Income | 54.90M-58.7% |
| EPS | 0.42-62.8% |
| Shares Out | 108.10M |
| PE Ratio | 224.81 |
| Forward PE | 27.18 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 143,296.504 |
| Open | 118.52 |
| Previous Close | 119.60 |
| Day's Range | 115.80 - 118.97 |
| 52-Week Range | 28.66 - 126.38 |
| Beta | 0.45 |
| Analysts | Buy |
| Price Target | 125.33(+7.50%) |
| Earnings Date | Nov 4, 2026 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About CORT
Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsychiatric disorders across the United States. Its primary commercial offering is Korlym (mifepristone) tablets, an oral medication taken once daily. Korlym is prescribed for adult patients diagnosed with endogenous Cushing's syndrome who suffer from hyperglycemia due to hypercortisolism, particularly those with type 2 diabetes or glucose intolerance, and for whom surgical options have either failed or are not viable. The company's development pipeline is robust, featuring relacorilant, which is being advanced for Cushing's syndrome. It is also investigating a combination of relacorilant with nab-paclitaxel; this pairing has concluded Phase II clinical trials for advanced ovarian tumors and is additionally being studied for conditions involving cortisol excess. Furthermore, Corcept is developing distinct selective cortisol modulators for specific indications such as metastatic castration-resistant prostate cancer and antipsychotic-induced weight gain, alongside research into FKBP5 gene expression assays.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$CORT stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in CORT holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by CORT's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
CORT Estimated quarterly lobbying spending
Source: U.S. Senate LDA
CORT Revenue by Segment
| Segment | Revenue | % of All |
|---|---|---|
| Hypercortisolism Products | $208.58M | 81.43% |
| Lifyorli | $47.56M | 18.57% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New CORT patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to CORT from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in CORT
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $328.73M |
| VBVanguard Morningstar Small-Cap ETF | $237.98M |
| VBKVanguard Morningstar Small-Cap Growth ETF | $136.59M |
| VXFVanguard Extended Market ETF | $125.83M |
| FBTFirst Trust NYSE Arca Biotechnology Index Fund | $117.82M |
| MDYState Street SPDR S&P MIDCAP 400 ETF Trust | $84.23M |
Estimated from each fund’s disclosed top holdings × AUM
CORT Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from CORT’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score